• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home Weekly Rewinds

2 Minute Medicine Rewind November 14, 2016

byDavid Ouyang
November 17, 2016
in Weekly Rewinds
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis 

Celecoxib is a selective COX-2 inhibitor used for analgesia as an alternative to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), however the cardiovascular risk profile is controversial. In this multicenter, industry sponsored, randomized control trial, 24,081 patients with osteoarthritis or rheumatoid arthritis were randomized to daily celecoxib, naproxen, or ibuprofen and followed for a primary endpoint of cardiovascular death, myocardial infarction, or nonfatal stroke. This was a non-inferiority trial with a prespecified boundary of an HR of 1.12 or less. In the trial, 2.3% of patients in the celecoxib arm experienced the primary endpoint, compared to 2.5% of patients in the naproxen arm (HR for celecoxib 0.93, p < 0.001 for inferiority), and 2.7% in the ibuprofen arm (HR for celecoxib 0.85, p < 0.001 for inferiority). 68.8% of patients discontinued the study drug, however similar results were found in on-treatment analysis. For patients taking celecoxib, there was statistically significantly less gastrointestinal bleeding and renal dysfunction. The authors conclude celecoxib is noninferior to ibuprofen or naproxen in relation to cardiovascular health.

Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease

There continues to exist significant variation in the intensity of statin therapy in patients with atherosclerotic cardiovascular disease, however there is limited data on the differences in clinical outcomes based on the intensity of statin therapy. In this retrospective cohort study of 509,766 patients with atherosclerotic heart disease in the US Veterans Affairs health care system, investigators compared 1 year mortality with the intensity of statin therapy. The investigators found a dose-dependent effect on 1 year mortality with 4.0% mortality in patients receiving high-intensity statin, 4.8% mortality in patients receiving moderate-intensity statin, 5.7% mortality in patients receiving low-intensity statin, and 6.6% mortality in patients receiving no statin. Additionally, patients receiving maximum doses of a high intensity statin had lower mortality (HR 0.9, 95% CI 0.87 to 0.94) compared to patients receiving submaximal doses of a high intensity statin. In this cohort of patients in the VA healthcare system, the intensity of statin therapy was associated with survival benefit.

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

Peripheral artery disease from atherosclerosis is medically managed with antiplatelet pharmacotherapy such as aspirin and clopidogrel. Ticagrelor is a more potent P2Y12 antiplatelet agent than clopidogrel and is tried to assess its clinical efficacy. In this randomized, multicenter, industry sponsored trial, 13,885 patients with symptomatic peripheral artery disease were randomized to either ticagrelor or clopidogrel and followed for a median of 30 months for a primary endpoint of cardiovascular death, myocardial infarction, or ischemic stroke. The study found a nonstatistically significant difference between ticagrelor and clopidogrel (10.8% vs. 10.6%, HR 1.02, p = 0.65). There was also similar rates of limb ischemia (1.7%) and major bleeding (1.6%) in each group. This study did not show clinical benefit in the use of ticagrelor over clopidogrel.

Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence

RELATED REPORTS

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

Anakinra is an interleukin 1b recombinant receptor antagonist and is thought to be potentially beneficial in colchicine-resistant and corticosteroid-dependent recurrent pericarditis. In this, multicenter, placebo controlled, randomized trial of 21 Italian patients with recurrent pericarditis, patients were randomized to anakinra or placebo and followed for recurrent pericarditis. After a median follow-up of 14 months, there was a statistically significant decrease in the number of recurrences (90% vs. 18.2%, p < 0.001). For patients on anakinra, there were local skin reactions, herpes zoster, transaminitis, and ischemic optic neuritis. Although this was a small trial of a rare condition, further studies of anakinra should be undertaken to confirm its efficacy in recurrent pericarditis.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: AnakinraCelecoxibnaproxenstatin
Previous Post

Combination therapy effectively treats hepatocellular carcinoma in mice [PreClinical]

Next Post

Ustekinumab linked with efficacy in treatment of Crohn’s disease: The UNITI-1 & 2, IM-UNITI trials

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Cardiology

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

April 7, 2022
#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa
StudyGraphics

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

December 23, 2021
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

November 16, 2021
Computed tomography improves diagnostic certainty in the emergency department
Cardiology

Comparing incidence and severity of COVID-19 between statin users and non-users

October 26, 2021
Next Post
Anti-TNF therapy for inflammatory bowel disease may induce skin lesions

Ustekinumab linked with efficacy in treatment of Crohn’s disease: The UNITI-1 & 2, IM-UNITI trials

USPSTF recommends biennial screening mammography in 50 to 74 year-old women

Palbociclib taken with letrozole increases progression-free survival in breast cancer patients

Engineered stem cells mitigate liver damage caused by radiation [PreClinical]

Stem cell transplant in primates treats injured hearts [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.